Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Prime Medicine, Inc. - Common Stock (NQ:PRME)

5.120 +0.470 (+10.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Prime Medicine, Inc. - Common Stock

< Previous 1 2 3 Next >
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
PRME Revenue Misses by 73%
Via The Motley Fool
Align Technology Posts Downbeat Earnings, Joins Confluent,FormFactor And Other Big Stocks Moving Lower In Thursday Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Meta Platforms Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Hut 8, Greenbrier And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Citi Downgrade Sparks Retail Chatter On Prime Medicine Amid Cash Runway Uncertainty
The biotech firm announced a restructuring to focus on its liver disease programs while cutting costs and workforce amid ongoing development challenges. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
This MongoDB Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
 
Via Benzinga
6 Analysts Assess Prime Medicine: What You Need To Know
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Prime Medicine Announces Layoffs, CEO Transition: Retail Gets More Bullish
The company said Keith Gottesdiener will step down as the chief executive, while CFO Allan Reine will succeed him. 
Via Stocktwits
Topics Workforce
Cathie Wood's Ark Invest Offloads Uipath, Prime Medicine, And Repare Therapeutics
On April 11th, 2025, Cathie Wood's Ark Invest sold shares in UiPath, Prime Medicine, and Repare Therapeutics, with notable gains and losses. 
Via Benzinga
Why Prime Medicine Stock Was Climbing Higher This Week
Via The Motley Fool
Why Prime Medicine Stock Is Soaring Today
Via The Motley Fool
Cathie Wood's Ark Invest Continues To Offload UiPath, Roblox: Loads Up On GitLab, Ibotta
Ark Invest's Cathie Wood-led funds made significant trades involving GitLab, Intellia, Prime Medicine, UiPath, Ibotta, Roblox, Repare Therapeutics, and CareDx. 
Via Benzinga
12 High-Growth Stocks That Could Deliver Parabolic Returns
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
Why I Keep Buying These 14 Incredible Growth Stocks
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
Changes are afoot at the company, and investors welcomed them. 
Via The Motley Fool
Dow Dips 300 Points; Emcore Shares Spike Higher
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Crude Oil Moves Higher; Prime Medicine Shares Spike Higher
 
Via Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
Prime Medicine enters a strategic collaboration with Bristol Myers Squibb to develop next-gen T-cell therapies, securing $110 million upfront with potential for $3.5 billion in milestones. The company... 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.